Research Article
Volume 14 Issue 9 - 2022
Does rTMS Help in Improving the Global Neuropsychological Functioning of Parkinson’s Disease Patients: A Pilot Study
Ashima Nehra1*, Rhythm Makkar1, Ruchita Hazrati1, Avneesh Narain1, Priya Sharma1, Priyanka Bhat2, Hem Chandra Sati3, Rajesh Kumar Singh2, Roopa Rajan2, Maroof Ahmad Khan3 and Achal Kumar Srivastava2
1Neuropsychology, Neurosciences Centre, All India Institute of Medical Sciences, New Delhi, India
2Department of Neurology, Neurosciences Centre, All India Institute of Medical Sciences, New Delhi, India
3Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India
*Corresponding Author: Ashima Nehra, Clinical Psychology (nsc), Neuropsychology, Neurosciences Centre, All India Institute of Medical Sciences, New Delhi, India.
Received: August 09, 2022; Published: August 26, 2022




Abstract

Parkinson’s disease (PD) is a neurodegenerative disease that on average causes 3.2 million DALY’s (Disability-adjusted life years) and over 2,00,000 deaths globally [1]. The disease presents with debilitating cognitive and behavioural symptoms leading to a compromised quality of life. Repetitive Transcranial Magnetic Stimulation (rTMS) is a contemporary neuromodulation technique that applies focal stimulation and brings about changes in cortical excitability in a specific brain region. There is a lacuna in the existing literature on the relationship between rTMS and neuropsychology of PD patients, and hence a pilot study was planned to understand the effect of rTMS on the global neuropsychological functioning of PD patients. A 20Hz rTMS intervention was conducted over the left dorsolateral prefrontal cortex (dlpfc). 23 patients diagnosed with PD that passed the eligibility criteria received 5 sessions/week x 2 weeks = 10 sessions of rTMS. Patients were assessed on memory, executive functioning, quality of life, behavioural symptoms, and clinical impairment at baseline, 1 month and 3 months post last day of intervention. Wilcoxon Sign Rank test (p = 0.05) was used to compare differences in overall neuropsychological functioning before and after rTMS. It was found that rTMS at 20Hz over left dlpfc improved delayed general and auditory memory after 10 sessions. This suggests that rTMS when accompanied by usual pharmacological therapy could be beneficial for PD patients with memory concerns.

Keywords: Neuropsychology; Neuroscience; Parkinson’s Disease; Repetitive Transcranial Magnetic Stimulation; Cognition; Memory

References

  1. GBD 2016 Parkinson's Disease Collaborators. “Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016”. Lancet Neurology11 (2018): 939-953.
  2. Jiang Y., et al. “Effect of rTMS on Parkinson's cognitive function: a systematic review and meta-analysis”. BMC Neurology1 (2020): 377.
  3. Aarsland D., et al. “Parkinson disease-associated cognitive impairment”. Nature Reviews Disease Primers47 (2021).
  4. Arun MP., et al. “Relationship of depression, disability, and quality of life in Parkinson's disease: a hospital-based case-control study”. Neurology India2 (2011): 185-189.
  5. Holroyd S., et al. “Depression is associated with impairment of ADL, not motor function in Parkinson disease”. Neurology 64 (2005): 2134-2135.
  6. Nehra A., et al. “How cultural beliefs buffer against suicide in Parkinson's disease patients with Depression: An Indian Karmic Perspective”. Movement Disorders 35 (2020): 339-339.
  7. Cosgrove Jeremy., et al. “Cognitive impairment in Parkinson's disease”. Postgraduate Medical Journal1074 (2015): 212-220.
  8. Forsaa EB., et al. “A 12-year population-based study of psychosis in Parkinson disease”. Archives of Neurology8 (2010): 996-1001.
  9. Porrselvi AP and Shankar V. “Status of Cognitive Testing of Adults in India”. Annals of Indian Academy of Neurology4 (2017): 334-340.
  10. Roheger M., et al. “Progression of Cognitive Decline in Parkinson's Disease”. Journal of Parkinson's Disease2 (2018): 183-193.
  11. Sanchez-Luengos I., et al. “Effectiveness of Cognitive Rehabilitation in Parkinson's Disease: A Systematic Review and Meta-Analysis”. Journal of Personalized Medicine5 (2021): 429.
  12. Brys M., et al. “Multifocal repetitive TMS for motor and mood symptoms of Parkinson disease: A randomized trial”. Neurology18 (2016): 1907-1915.
  13. Jivraj J and Ameis SH. “Is Repetitive Transcranial Magnetic Stimulation (rTMS) Ready for Clinical Use as a Treatment Tool for Mental Health Targets in Children and Youth?” Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent2 (2022): 93-99.
  14. Rabey JM., et al. “Repetitive transcranial magnetic stimulation combined with cognitive training is a safe and effective modality for the treatment of Alzheimer's disease: a randomized, double-blind study”. Journal of Neural Transmission5 (2013): 813-819.
  15. Lisanby Sarah and Belmaker Robert. “Animal models of the mechanisms of action of repetitive transcranial magnetic stimulation (RTMS): Comparisons with electroconvulsive shock (ECS)”. Depression and Anxiety 12 (2000): 178-187.
  16. Mishra BR., et al. “Repetitive transcranial magnetic stimulation in psychiatry”. Annals of Indian Academy of Neurology4 (2011): 245-251.
  17. Dalhuisen I., et al. “rTMS combined with CBT as a next step in antidepressant non-responders: a study protocol for a randomized comparison with current antidepressant treatment approaches”. BMC Psychiatry 22 (2022): 88.
  18. Mishra BR., et al. “Repetitive transcranial magnetic stimulation in psychiatry”. Annals of Indian Academy of Neurology4 (2011): 245-251.
  19. S. Food and Drug Administration. FDA permits marketing of transcranial magnetic stimulation for treatment of obsessive compulsive disorder (2018).
  20. Rektorová I and Anderková Ľ. “Noninvasive Brain Stimulation and Implications for Nonmotor Symptoms in Parkinson's Disease”. International Review of Neurobiology 134 (2017): 1091-1110.
  21. Boggio PS., et al. “Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression”. Movement Disorders: Official Journal of the Movement Disorder Society9 (2005): 1178-1184.
  22. Dinkelbach L., et al. “Non-invasive brain stimulation in Parkinson's disease: Exploiting crossroads of cognition and mood”. Neuroscience and Biobehavioral Reviews 75 (2017): 407-418.
  23. Randver R. “Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex to alleviate depression and cognitive impairment associated with Parkinson's disease: A review and clinical implications”. Journal of the Neurological Sciences 393 (2018): 88-99.
  24. Ivraj J and Ameis SH. “Is Repetitive Transcranial Magnetic Stimulation (rTMS) Ready for Clinical Use as a Treatment Tool for Mental Health Targets in Children and Youth?” Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academiecanadienne de psychiatrie de l'enfant et de l'adolescent2 (2022): 93-99.
  25. MacMaster FP., et al. “Repetitive Transcranial Magnetic Stimulation in Youth With Treatment Resistant Major Depression”. Frontiers in Psychiatry 10 (2019): 170.
  26. Jiang Y., et al. “Effect of rTMS on Parkinson's cognitive function: a systematic review and meta-analysis”. BMC Neurology1 (2020): 377.
  27. Swati B., et al. “Dementia Assessment by Rapid Test (DART): An Indian Screening Tool for Dementia”. The Journal of Alzheimer Disease and Parkinsonism 5 (2015): 198.
  28. Chopra S., et al. “Development of neuropsychological evaluation screening tool: An education-free cognitive screening instrument”. Neurology India2 (2018): 391-399.
  29. Hoehn MM and Yahr MD. “Parkinsonism: onset, progression, and mortality”. Neurology2 (1998): 318.
  30. Pascual-Leone A and Hallett M. “Induction of errors in a delayed response task by repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex”. Neuroreport 5 (1994): 2517-2520.
  31. Wechsler D. “Wechsler memory scale”. Psychological Corporation (1945).
  32. Pershad D and Verma K. “PGI Battery of Brain Dysfunction”. National Psychological Corporation (1990).
  33. Stuss DT., et al. “Stroop performance in focal lesion patients: Dissociation of processes and frontal lobe lesion location”. Neuropsychologia 39 (2001): 771-786.
  34. Rao SL., et al. “Nimhans Neuropsychological Battery”. National Institute of Mental Health and Neurosciences (2004).
  35. Ruff RM., et al. “Benton Controlled Oral Word Association Test: reliability and updated norms”. Archives of Clinical Neuropsychology4 (1996): 329-338.
  36. Rao SL., et al. “Nimhans Neuropsychological Battery”. National Institute of Mental Health and Neurosciences (2004).
  37. De Boer AG., et al. “Quality of life in patients with Parkinson's disease: development of a questionnaire”. Journal of Neurology, Neurosurgery, and Psychiatry1 (1996): 70-74.
  38. Schwab RS and England AC. “Projection techniques for evaluating surgery in Parkinson's Disease. Third Symposium on Parkinson's Disease, Royal College of Surgeons in Edinburgh”. E. and S. Livingstone Ltd (1969).
  39. Corrigan JD. “Development of a scale for assessment of agitation following traumatic brain injury”. Journal of Clinical and Experimental Neuropsychology2 (1989): 261-277.
  40. Starkstein SE and Merello M. “The Unified Parkinson's Disease Rating Scale: validation study of the mentation, behavior, and mood section”. Movement and Disorders15 (2007): 2156-2161.
  41. Solé-Padullés C., et al. “Repetitive transcranial magnetic stimulation effects on brain function and cognition among elders with memory dysfunction. A randomized sham-controlled study”. Cerebral Cortex10 (2006): 1487-1493.
  42. Cui D., et al. “Beneficial Effect of High-Frequency Repetitive Transcranial Magnetic Stimulation for the Verbal Memory and Default Mode Network in Healthy Older Adults”. Frontiers in Aging Neuroscience 14 (2022): 845912.
  43. Wei W., et al. “Acute improvement in the attention network with repetitive transcranial magnetic stimulation in Parkinson's disease”. Disability and Rehabilitation (2021): 1-9.
  44. Jiang Y., et al. “Effect of rTMS on Parkinson's cognitive function: a systematic review and meta-analysis”. BMC Neurology1 (2020): 377.
  45. Málly J., et al. “Follow up study: The influence of rTMS with high and low frequency stimulation on motor and executive function in Parkinson's disease”. Brain Research Bulletin 135 (2017): 98-104.
  46. Badre D and Wagner AD. “Selection, integration, and conflict monitoring; assessing the nature and generality of prefrontal cognitive control mechanisms”. Neuron3 (2004): 473-487.
  47. Hart H., et al. “Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects”. JAMA Psychiatry2 (2013): 185-198.
  48. Nehra A., et al. “Enhancing Quality of Life in Indian Parkinson's Disease Patients with Improved Measurement of Psychological Domains: A Perspective”. Annals of Indian Academy of Neurology2 (2021): 132-137.
  49. Furukawa T., et al. “Effects of low-frequency repetitive transcranial magnetic stimulation in Parkinson’s disease”. Tokai Journal of Experimental and Clinical Medicine3 (2009): 63-71.
  50. Brys M., et al. “Multifocal repetitive TMS for motor and mood symptoms of Parkinson disease: A randomized trial”. Neurology18 (2016): 1907-1915.
  51. J Málly. “The Effect of rTMS on the Executive Function and Bradykinesia in Parkinson’s Disease”. Clinical Neurophysiology10 (2013): e182.
  52. Murdoch Bruce., et al. “Retracted: Treatment of articulatory dysfunction in Parkinson’s disease using repetitive transcranial magnetic stimulation”. European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies 19 (2011): 340-347.
  53. Del Olmo MF., et al. “Transcranial magnetic stimulation over dorsolateral prefrontal cortex in Parkinson's disease”. Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology1 (2007): 131-139.
  54. Ilieva Irena and Alexopoulos., et al. “Age-Related rTMS Effects on Executive Function in Depression: a Systematic Review”. The American Journal of Geriatric Psychiatry (2017): 26.
  55. J Málly. “The Effect of rTMS on the Executive Function and Bradykinesia in Parkinson’s Disease”. Clinical Neurophysiology10 (2013): e182.
  56. Mishra BR., et al. “Repetitive transcranial magnetic stimulation in psychiatry”. Annals of Indian Academy of Neurology 14.4 (2011): 245-251.
  57. Hertrich I., et al. “The Role of the Dorsolateral Prefrontal Cortex for Speech and Language Processing”. Frontiers in Human Neuroscience (2021): 15.
Citation: Ashima Nehra., et al. “Does rTMS Help in Improving the Global Neuropsychological Functioning of Parkinson’s Disease Patients: A Pilot Study”. EC Neurology 14.9 (2022): 05-14.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


December Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the November issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before December 23, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.